PET Scanning


Positron emission tomography (PET)  scanning is an imaging modality with primary use in the field of oncology. It utilizes radiotracers for measuring various metabolic processes in the body. Various changes in metabolism, blood flow, and regional chemical composition can be analyzed by it. Radio-tracers can be injected, swallowed, or inhaled depending upon the site of the body being examined, and the tracer gets trapped in various tissues of the body depending upon the affinity. Areas of higher activity show higher uptake and brighter spots on images. Unstable nuclei of radioactive-tracer emit positrons that produce gamma rays upon the combination with the neighboring electrons. The gamma rays are detected by a ring of detectors in the scanner. A computer then uses this data to create a 3D-image of the tracer in the body. Various tracers are utilized depending on the targets.


The tracer may be administered via an intravenous route, orally or via inhalation. The tracer takes some time to distribute throughout the body. A contrast may be administered intravenously or orally if a PET-CT is to be done. Positioning depends upon the site to be scanned. The PET machine has a central hole through which the patient slides through. First images are generally scout images to assess whether the positioning is correct. Sometimes breath-holding maybe required. The scan takes anything from 30 minutes to 1 hour.



Tracers used commonly include fluorine-18 (18F) fluoro-deoxyglucose (FDG), called [18F] FDG PET. 18F-FDG being a glucose analog, gets picked up by the cells instead of regular glucose for metabolism. Glucose gets phosphorylated by hexokinases. The values of the mitochondrial form of this enzyme are raised in cancers that are rapidly growing. In locations of cancer, the metabolic activity is quite high; hence the glucose uptake is quite high. So this 18F-FDG also gets taken up quite significantly in these locations, and then this shows up as a bright spot on the PET scan. This helps in the detection of metastasis also. Typical doses amount to 7.5 mSv.[1] In the generation of 18-F FDG, the hydroxyl group is replaced by radioactive Fluorine. This hydroxyl group is essential in glucose metabolism steps & its absence causes the stoppage of further reactions in the cells. Most tissues (except liver & kidney) can’t remove the phosphate which hexokinase has added. So, the 18F-FDG gets trapped inside the cell till its decay. This is because phosphorylation of sugar leads to the development of ionic charge, which prevents the exit of the sugar from the cell till its decay. Hence tissues with higher glucose uptake & utilization like brain, liver, kidneys, and most of the cancers (due to Warburg effect) show intensive radio-labeling.

FDG-PET is used for diagnosis, staging, and monitoring cancers, particularly in Hodgkin's lymphoma,[2] non-Hodgkin lymphoma,[3], and lung cancer.[4][5][6] In a study, the likelihood ratio for malignancy in a solitary pulmonary nodule with an abnormal FDG-PET scan was 7.11. This study suggested that the FDG-PET scan is more accurate than the standard criteria for diagnosis. FDG-PET can be used as an adjunct test in solitary pulmonary nodule evaluation.[7] In assessing FDG-PET in staging patients with non-small cell carcinoma, FDG-PET had a higher sensitivity (71% vs 43%), positive predictive value (44% vs 31%), negative predictive value (91% vs 84%) & accuracy (76% vs 68%) than computed tomography (CT) scan for N2 lymph nodes. Whereas, FDG-PET had a higher sensitivity (67% vs. 41%) but lower specificity (78% vs. 88%) than CT scan for N1 lymph nodes. It accurately upstaged 28 patients (7%) with unsuspected metastasis & down-staged 23 patients (6%). Hence it can be concluded that the FDG-PET scan allows for improved patient selection & accurately stages the mediastinum. However, there were many false positives lymph nodes, and it may miss N2 disease in the #5, #6, and #7 stations.

A positive FDG-PET scan means a tissue biopsy is indicated in that location.[8] In FDG-PET evaluation of cancers of the esophagus and gastroesophageal junction, FDG-PET had lower accuracy in the diagnosis of locoregional nodes (N1–2) than combined CT (computed tomography) and EUS (endoscopic ultrasound) (48% vs. 69%) because of a lack of sensitivity (22% vs. 83%). The accuracy for distant nodal metastasis was significantly higher for FDG-PET than the combined use of CT & EUS. Sensitivity was no different, however, specificity was higher. FDG-PET correctly upstaged five patients (12%) from N1–2 stage to the M+Ly stage, while one was falsely downstaged by FDG-PET scanning.[9] In a study on the role of FDG PET scan in colorectal cancer screening in asymptomatic adults, it was found that sensitivity of FDG-PET to detect primary colorectal cancer is high, primary colorectal cancer being detected with FDG PET in a resectable stage. FDG-PET could detect large size (> 0.7 cm) and pre-malignant change of colonic adenomas. It’s possible to differentiate adenoma from carcinoma of the colon by assessing the increase in the rate of glycolysis in carcinoma.[10] 

FDG-PET has a role in the detection of recurrent cervical cancer in symptomatic and asymptomatic women. Thiry percent of asymptomatic women had recurrent disease detected by PET scan compared to 66.7% of symptomatic women. The sensitivity of PET for recurrent disease in asymptomatic women was 80.0%, specificity 100%, the positive predictive value of 100% and a negative predictive value of 88.9%. For symptomatic women, the sensitivity of PET was 100%, specificity 85.7%, the positive predictive value of 93.3%, and negative predictive value of 100%. Hence, whole-body PET can be a sensitive imaging modality for the detection of recurrent cervical carcinoma in both symptomatic and asymptomatic women also.[11] 

The 68-gallium DOTA peptide is used to detect primary and metastatic neuroendocrine tumors (NETs). NETs express somatostatin receptors (SSTRs), with SSTR2 (51%) of cases, followed by SSTR1 (47%) and SSTR5 (43%). The remaining SSTR4 (36%) and SSTR3 (23%) have low expression levels.[12][13] The 68-gallium DOTA PET-CT was able to detect significantly more lesions in patients with negative anatomical imaging compared with 111-ln-octreoscan (30 vs. 2; p = 0.028). Pfeifer et al. reported a sensitivity of 88% for ln-octreoscan in comparison to 97% for the 64-Cu DOTA PET-CT.[14] Srirajaskanthan et al. found 68-Gallium DOTA PET-CT scans to detect 74.3% of the lesions, whereas 111-ln-octreoscan detected 12% of the lesions.[15] The 68-Gallium DOTA PET-CT was found helpful in the detection of NETs in symptomatic patients with no evidence of disease on the basis of anatomical imaging and endoscopic evaluation, with or without biochemical evidence of disease. It significantly altered treatment in these patients who, on follow-up, had improvement in symptoms. Patients with a difficult diagnosis should be offered the 68-Gallium DOTA PET-CT.

Other tracers being used include C-labelled metomidate (11C-metomidate) for detecting adrenocortical tumors.[16][17] F-DOPA PET-CT ( F-DOPA PET-CT) is shown to be a sensitive alternative to find and localize pheochromocytoma than MIBG (meta-iodo benzyl guanidine) scan.[18][19]


Areas of high radiotracer uptake are associated with higher brain activity. It measures indirectly the flow of blood through the brain, which has been correlated with areas of higher brain activity. Oxygen-15 is used for this.

Alzheimer disease results in decreased brain metabolism of both glucose and oxygen. [18F] FDG PET of the brain is used to differentiate Alzheimer disease from other dementias. Perfusion, glucose metabolism, and Aβ imaging have an established role and are included in the revised diagnostic criteria as important biomarkers. Florbetapir F18, flutemetamol F18, and florbetaben F18 are used to detect amyloid-beta plaques. Other targets include tau protein and neuro-inflammation. Protein kinase C (PKC) promotes the induction of alphasecretase or “a disintegrin and metalloprotease (ADAM)” non-amyloidogenic cleavage of amyloid precursor protein (APP) and hence have an important role in the acquisition and maintenance of memory in Alzheimer disease (AD). Deficits in PKC are seen early in the course of the disease. A selective PKC inhibitor, enzastaurin (LY317615), has recently been radiolabeled with C to be used as a potential probe for PET imaging applications.[20] P-Glycoprotein (P-gp) in the blood-brain barrier (BBB) has been thought to play a role in Aβ clearance from the brain. [11C] verapamil is a radiolabeled P-gp substrate used in PET studies, showing lower P-gp expression in subjects older than 75 years, but the increased expression in the young.[21] 

The cholinergic deficit has been studied with PET, the radio-labelled analog of acetylcholine, such as N-[(11) C]-methyl-4-piperidyl acetate (MP4A). Decreased cortical uptake is found in AD patients, with a greater reduction in Lewy body dementia more so in the posterior cingulate gyrus.[22] Radiolabeled cholinesterase inhibitors used for AD treatment like donepezil ([11C]donepezil) are used in assessing donepezil binding sites. A fluorinated tracer, 3-(benzyloxy)-1-(5-[18F]fluoropentyl)-5-nitro1H-indazole, [18F]-IND1, structurally related to the acetylcholinesterase inhibitor CP126,998, has been developed for the detection of acetylcholinesterase changes in AD patients.[23][24] PET scanning has resulted in improvement in the knowledge of the pathophysiology of atypical Parkinsonism disorders and may be used as supportive criteria for differential diagnosis of these conditions.[25] Brain PET imaging with FDG may be useful in seizure focus localization, which appears hypo-metabolic during an interictal scan. Various radiotracers for specific neuroreceptors have been developed like [11C] raclopride, [18F] fallypride and [18F] desmethoxyfallypride for dopamine D2/D3 receptors, [11C] McN 5652 and [11C] DASB for serotonin transporters, [18F] Mefway for serotonin 5HT1A receptors, [18F] nifene for nicotinic acetylcholine receptors or enzyme substrates (6-FDOPA for AADC enzyme). These help in the localization of these neuroreceptors in the pathogenesis of various neurologic diseases.

Neuropsychology: PET scanning helps delineate a link between specific processes and brain activity.

Psychiatry: Radiotracers binding to dopamine, serotonin, opioid, and cholinergic receptors are used to study their roles in various psychological disorders.

Stereotactic Surgery and Radiosurgery: PET-image guided surgeries are now being done.


[18F]FDG-PET helps to identify hibernating myocardium. Imaging of atherosclerosis to detect patients at risk of stroke may also be done. Using FDG PET, we can detect inflammation quite early even before morphological and irreversible vascular changes are seen. Hence early diagnosis and treatment of large-vessel vasculitis are possible.[26]

Myocardial Perfusion Tracers: Tracers have been developed to visualize the myocardial blood flow, including nitrogen-13 (13N)-labeled ammonia and oxygen-15 –labeled water ([15O]-H2O) and rubidium-82 (82Rb)-chloride and copper-62 (62Cu)-labeled pyruvaldehyde bis (N4-methylthio-semicarbazone) or [62Cu]-PTSM. Only 13N and 82Rb are approved by the FDA.[27]

Myocardial Metabolic Tracers: The heart uses primarily free fatty acids (FFA) in oxidative metabolism. Ischemic & hypoxic myocardium prominently utilize glucose because of increased anaerobic glycolysis rate. Tracers to visualize this include  18F-FDG and carbon-11–labeled palmitate and acetate. PET with myocardial perfusion and [18F]-FDG quite accurately assesses myocardial viability & is considered the gold standard for assessing myocardial viability. Predicting functional recovery of heart, improvement in congestive heart failure symptoms, exercise capacity, quality of life, cardiac events, remodeling, and long-term survival is possible with PET.[27]

Infectious Diseases

PET can be used to image bacterial infections via 18F-FDG, by identifying infection-associated inflammatory response. Agents include [18F]maltose,[23] [18F]maltohexaose & [18F]2-fluorodeoxysorbitol (FDS).[28] FDS importantly targets only Enterobacteriaceae. Applications include FUO, vascular graft infections, musculoskeletal infections including osteomyelitis, joint prosthesis infections & diabetic foot infection. FDG-PET in osteomyelitis has improved spatial resolution over SPECT imaging, thereby allowing more accurate localization, which can be further improved by adding CT.[29] FDG-leukocyte imaging has been found comparable to In-oxine-leukocyte scintigraphy to detect infection. Applications of this technique include graft imaging, colonic inflammation & peritoneal tuberculosis.[30][31][32][33][34] 

Autoimmune Diseases

The upcoming role of PET is included in the new group of diseases called IgG4 diseases. FDG PET/CT isn’t included in standard sarcoidosis workup, but it’s efficient in the initial diagnosis and follows up of disease management. It can help to assess cardiac involvement, response to treatment, and evaluation of reversible granulomas as well as to determine the best site for biopsy.[35] 18F-FDG-PET can differentiate normal thyroid parenchyma from diffuse inflammatory changes of the thyroid gland in patients with autoimmune thyroid diseases (AITD).[36] FDG uptake in rheumatoid arthritis in affected joints reflects disease activity with the correlation between FDG and clinical parameters, monitoring the response to therapy also. FDG-PET/CT shows a high diagnostic value for polymyalgia rheumatica in differential diagnosis from rheumatoid arthritis.[37]

Musculoskeletal System Diseases

PET provides muscle activation data about deep-lying muscles compared with techniques like electromyography, which is useful in superficial muscles only. [18F]-NaF is used to measure regional bone metabolism and blood flow. [18F]NaF is recently being used in studying bone metastasis also.[38]

Interfering Factors

Strenuous exercises can lead to a considerable increase in radiotracer uptake by various tissues & hence should be avoided prior to imaging.[39] Twenty-four hours before the scan, a low-carbohydrate, no-sugar diet is advised. Allowable foods include meat, cheese, egg, and vegetables without starch. Foods not allowed include cereals, pasta, milk, bread, and sugar. Six hours before the scan, not eating or drinking anything is recommended. Metal may interfere; hence it is preferably removed. Other interfering factors include high blood glucose levels in diabetics; caffeine, alcohol, or tobacco within 24 hours of the procedure; excessive anxiety which affects brain function; medicines like insulin, tranquilizers, and sedatives; neurological or psychiatric conditions, which prevent the ability to lie still.


PET-CT has the complications involved with contrast administration, including possible anaphylaxis, contrast-induced nephropathy, etc. Generally, the radiotracers used don’t cause any significant side effects.

Patient Safety and Education

PET-CT involves radioactive material, and exposure to radiation is there. 18F-FDG has an effective radiation dose of 14 mSv. Potential side effects of radiation as they hold for other imaging modalities are seen in PET scan also. In a standard PET scan amount of radiation is quite less, of the range of 8 mSv, about equivalent to that received from natural sources like the sun. PET-CT uses higher levels of radiation of the range of 24mSv. Pregnant ladies shouldn’t undergo a PET scan unless absolutely necessary as radioactivity can affect the fetus. A breastfeeding woman should limit close contact with infants or pregnant women for up to 12 hours. Breast milk may be discarded until 12 hours & after about 24 hours, it is considered safe to breastfeed again.

Clinical Significance

As mentioned above, PET scanning has a lot of potential in newer and newer fields of medicine, including the already established oncology & the upcoming fields like neurology, cardiology, psychiatry, and immunology. Many new uses are being discovered every day, and PET scanning is becoming a radiological test, which is quite sought after.

Article Details

Article Author

Mayank Kapoor

Article Editor:

Anup Kasi


10/3/2022 8:44:48 PM



Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of Radioactive Substances Advisory Committee. Nuclear medicine communications. 2000 Jan;     [PubMed PMID: 10732169]


Zaucha JM,Chauvie S,Zaucha R,Biggii A,Gallamini A, The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer treatment reviews. 2019 Jul;     [PubMed PMID: 31260900]


McCarten KM,Nadel HR,Shulkin BL,Cho SY, Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatric radiology. 2019 Oct     [PubMed PMID: 31620854]


Pauls S,Buck AK,Hohl K,Halter G,Hetzel M,Blumstein NM,Mottaghy FM,Glatting G,Krüger S,Sunder-Plassmann L,Möller P,Hombach V,Brambs HJ,Reske SN, Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin. Nuclear medicine. 2007;     [PubMed PMID: 17299649]


Steinert HC, PET and PET-CT of lung cancer. Methods in molecular biology (Clifton, N.J.). 2011;     [PubMed PMID: 21331927]


Chao F,Zhang H, PET/CT in the staging of the non-small-cell lung cancer. Journal of biomedicine     [PubMed PMID: 22577296]


Dewan NA,Shehan CJ,Reeb SD,Gobar LS,Scott WJ,Ryschon K, Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest. 1997 Aug;     [PubMed PMID: 9266877]


Cerfolio RJ,Ojha B,Bryant AS,Bass CS,Bartalucci AA,Mountz JM, The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. The Annals of thoracic surgery. 2003 Sep;     [PubMed PMID: 12963217]


Lerut T,Flamen P,Ectors N,Van Cutsem E,Peeters M,Hiele M,De Wever W,Coosemans W,Decker G,De Leyn P,Deneffe G,Van Raemdonck D,Mortelmans L, Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy. Annals of surgery. 2000 Dec;     [PubMed PMID: 11088069]


Chen YK,Kao CH,Liao AC,Shen YY,Su CT, Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan. Anticancer research. 2003 Sep-Oct;     [PubMed PMID: 14666651]


Unger JB,Ivy JJ,Connor P,Charrier A,Ramaswamy MR,Ampil FL,Monsour RP, Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecologic oncology. 2004 Jul;     [PubMed PMID: 15262145]


Shell J,Keutgen XM,Millo C,Nilubol N,Patel D,Sadowski S,Boufraqech M,Yang L,Merkel R,Atallah C,Herscovitch P,Kebebew E, 68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor. International journal of endocrine oncology. 2018 Feb     [PubMed PMID: 30112163]


Qian ZR,Li T,Ter-Minassian M,Yang J,Chan JA,Brais LK,Masugi Y,Thiaglingam A,Brooks N,Nishihara R,Bonnemarie M,Masuda A,Inamura K,Kim SA,Mima K,Sukawa Y,Dou R,Lin X,Christiani DC,Schmidlin F,Fuchs CS,Mahmood U,Ogino S,Kulke MH, Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016 Nov     [PubMed PMID: 27622342]


Pfeifer A,Knigge U,Binderup T,Mortensen J,Oturai P,Loft A,Berthelsen AK,Langer SW,Rasmussen P,Elema D,von Benzon E,Højgaard L,Kjaer A, 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Jun     [PubMed PMID: 25952736]


Srirajaskanthan R,Kayani I,Quigley AM,Soh J,Caplin ME,Bomanji J, The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Jun     [PubMed PMID: 20484441]


Khan TS,Sundin A,Juhlin C,Långström B,Bergström M,Eriksson B, 11C-metomidate PET imaging of adrenocortical cancer. European journal of nuclear medicine and molecular imaging. 2003 Mar;     [PubMed PMID: 12634969]


Minn H,Salonen A,Friberg J,Roivainen A,Viljanen T,Långsjö J,Salmi J,Välimäki M,Någren K,Nuutila P, Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Jun;     [PubMed PMID: 15181132]


Pacak K,Eisenhofer G,Carrasquillo JA,Chen CC,Li ST,Goldstein DS, 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension (Dallas, Tex. : 1979). 2001 Jul;     [PubMed PMID: 11463751]


Luster M,Karges W,Zeich K,Pauls S,Verburg FA,Dralle H,Glatting G,Buck AK,Solbach C,Neumaier B,Reske SN,Mottaghy FM, Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. European journal of nuclear medicine and molecular imaging. 2010 Mar;     [PubMed PMID: 19862519]


Wang M,Xu L,Gao M,Miller KD,Sledge GW,Zheng QH, [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C. Bioorganic     [PubMed PMID: 21320780]


Chiu C,Miller MC,Monahan R,Osgood DP,Stopa EG,Silverberg GD, P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations. Neurobiology of aging. 2015 Sep;     [PubMed PMID: 26159621]


Shimada H,Hirano S,Sinotoh H,Ota T,Tanaka N,Sato K,Yamada M,Fukushi K,Irie T,Zhang MR,Higuchi M,Kuwabara S,Suhara T, Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study. International journal of geriatric psychiatry. 2015 Nov;     [PubMed PMID: 26280153]


Valotassiou V,Malamitsi J,Papatriantafyllou J,Dardiotis E,Tsougos I,Psimadas D,Alexiou S,Hadjigeorgiou G,Georgoulias P, SPECT and PET imaging in Alzheimer's disease. Annals of nuclear medicine. 2018 Nov;     [PubMed PMID: 30128693]


Fernández S,Giglio J,Reyes AL,Damián A,Pérez C,Pérez DI,González M,Oliver P,Rey A,Engler H,Cerecetto H, 3-(Benzyloxy)-1-(5-[{sup}18{/sup}F]fluoropentyl)-5-nitro-1H-indazole: a PET radiotracer to measure acetylcholinesterase in brain. Future medicinal chemistry. 2017 Jun;     [PubMed PMID: 28632402]


Xu Z,Arbizu J,Pavese N, PET Molecular Imaging in Atypical Parkinsonism. International review of neurobiology. 2018;     [PubMed PMID: 30409257]


Pelletier-Galarneau M,Ruddy TD, PET/CT for Diagnosis and Management of Large-Vessel Vasculitis. Current cardiology reports. 2019 Mar 18;     [PubMed PMID: 30887249]


Takalkar A,Mavi A,Alavi A,Araujo L, PET in cardiology. Radiologic clinics of North America. 2005 Jan;     [PubMed PMID: 15693651]


Weinstein EA,Ordonez AA,DeMarco VP,Murawski AM,Pokkali S,MacDonald EM,Klunk M,Mease RC,Pomper MG,Jain SK, Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Science translational medicine. 2014 Oct 22;     [PubMed PMID: 25338757]


van der Bruggen W,Bleeker-Rovers CP,Boerman OC,Gotthardt M,Oyen WJ, PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Seminars in nuclear medicine. 2010 Jan;     [PubMed PMID: 19958846]


Vaidyanathan S,Patel CN,Scarsbrook AF,Chowdhury FU, FDG PET/CT in infection and inflammation--current and emerging clinical applications. Clinical radiology. 2015 Jul;     [PubMed PMID: 25917543]


Rini JN,Bhargava KK,Tronco GG,Singer C,Caprioli R,Marwin SE,Richardson HL,Nichols KJ,Pugliese PV,Palestro CJ, PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. Radiology. 2006 Mar;     [PubMed PMID: 16505395]


Bhattacharya A,Kochhar R,Aggrawal K,Sharma S,Mittal BR, 18F-FDG and FDG-labeled leukocyte PET/CT in peritoneal tuberculosis. Clinical nuclear medicine. 2014 Oct;     [PubMed PMID: 24368537]


Bhattacharya A,Kochhar R,Khaliq A,Sharma S,Mittal BR, Incidental detection of colonic inflammation on PET/CT using 18F-FDG-labeled autologous leukocytes. Clinical nuclear medicine. 2013 Feb;     [PubMed PMID: 23334139]


Yilmaz S,Asa S,Ozhan M,Halac M, Graft infection imaging with FDG and FDG-labeled leukocytes. Internal medicine (Tokyo, Japan). 2013;     [PubMed PMID: 23648725]


Akaike G,Itani M,Shah H,Ahuja J,Yilmaz Gunes B,Assaker R,Behnia F, PET/CT in the Diagnosis and Workup of Sarcoidosis: Focus on Atypical Manifestations. Radiographics : a review publication of the Radiological Society of North America, Inc. 2018 Sep-Oct;     [PubMed PMID: 30118393]


Małkowski B,Serafin Z,Glonek R,Suwała S,Łopatto R,Junik R, The Role of {sup}18{/sup}F-FDG PET/CT in the Management of the Autoimmune Thyroid Diseases. Frontiers in endocrinology. 2019;     [PubMed PMID: 31024448]


Kubota K,Yamashita H,Mimori A, Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. Seminars in nuclear medicine. 2017 Jul;     [PubMed PMID: 28583280]


Azad GK,Siddique M,Taylor B,Green A,O'Doherty J,Gariani J,Blake GM,Mansi J,Goh V,Cook GJR, Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of {sup}18{/sup}F-Fluoride Metabolic Flux Than with Measurement of {sup}18{/sup}F-Fluoride PET/CT SUV? Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Mar;     [PubMed PMID: 30042160]


Roef M,Vogel WV, The effects of muscle exercise and bed rest on [18F]methylcholine PET/CT. European journal of nuclear medicine and molecular imaging. 2011 Mar;     [PubMed PMID: 20967443]